Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Puerarin glycosylation derivative, medicine compound, preparation method and application thereof

A technology of puerarin glycosylation and derivatives, applied in the field of medicine, can solve the problems of reduced drug safety, fast elimination rate, adverse reactions, etc.

Inactive Publication Date: 2010-06-09
NANJING NORMAL UNIVERSITY +2
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The actual use is mainly clinical application by injection. With the extension of clinical use time, some adverse reactions appear, mainly because: 1) its elimination rate in the body is fast, the clinical use dose is relatively large, and the oral bioavailability is small; 2) The water solubility of puerarin is low, and most of the preparations contain co-solvents to increase the stability of the preparations, but the insoluble impurities also increase, causing certain adverse reactions to the human body, resulting in reduced drug safety

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Puerarin glycosylation derivative, medicine compound, preparation method and application thereof
  • Puerarin glycosylation derivative, medicine compound, preparation method and application thereof
  • Puerarin glycosylation derivative, medicine compound, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Inoculate the strain M. oxydans CGMCC 1788 in a 1000mL Erlenmeyer flask containing 300mL LB medium, and culture at 30°C with shaking at 220rpm for 24 hours; then transfer the cultivated culture solution into a 5L fermenter containing 3L LB at a speed of 500rpm , temperature 30°C, air flow 3L / min, tank pressure maintained at 0.1MPa, fermentation for 11-12h; then, centrifuge at 8000rpm for 10min to collect bacteria, wash once with 1 / 15M PBS (pH8.0), and centrifuge again to collect. The bacteria were transferred to 3L transformation solution, which contained 4mg / mL puerarin, 6% sucrose, 1 / 15M PBS, pH8.0, and transformed in a 5L reaction vessel at 500rpm, 30°C, and 3L / min ventilation After 48 hours, stop the reaction when the conversion rate of puerarin-7-O-glucoside reaches about 50%. Boil the transformation solution at 100°C for 10 minutes, cool to room temperature and centrifuge at 8000rpm for 10 minutes to remove bacteria and precipitates, take the supernatant transform...

Embodiment 2

[0063] The bacterial strain M.oxydans CGMCC 1788 was inoculated in a 250mL Erlenmeyer flask containing 00mL LB medium, 30°C, 220rpm shaking culture for 12 hours, and then, 1000rpm centrifuged for 10min to collect the bacteria, and 1 / 15M phosphate buffer solution (pH8.0 ) was washed once, and after centrifugation again, the obtained bacterial cells were suspended in 100 milliliters of 1 / 15M phosphate buffered saline solution. After the cells were broken using a Franch Press high-pressure cell disruptor, the cell fragments were removed by centrifugation at 12000 rpm, and the supernatant cell extract was collected. Add 100ml of transformation liquid, the transformation liquid contains 4mg / mL of puerarin, 6% sucrose, 1 / 15MPBS, pH8.0, 30°C, 220rpm shaking for 48h, the HPLC spectrum measured after the transformation liquid is diluted 100 times is shown in figure 2 . Boil the transformation solution at 100°C for 10 minutes, cool to room temperature and centrifuge at 8000rpm for 10 m...

Embodiment 3

[0072] Put 150mL of LB medium into a 500mL Erlenmeyer flask, a total of 1L of medium. After high-pressure steam sterilization at 121°C, insert Microbacterium oxydans CGMCC1788 seed solution, 30°C, 220rpm shaking culture for 12 hours, stop fermentation, collect bacterial cells by centrifugation, put them into a 500mL Erlenmeyer flask, add 150mL containing 0.02% puerarin -2% maltose 1 / 15mol / L phosphate buffer solution (pH8.0), 30°C, 200rpm shaking aeration to carry out the puerarin glycosylation resting cell transformation reaction, after 48h, stop the transformation reaction, centrifuge to remove the bacteria, The supernatant was separated by C18 preparative high-performance liquid chromatography to obtain puerarin-7-O-glucoside and puerarin-7-O-isomaltoside components respectively. °C until crystals are precipitated, the crystals are collected, washed and dried to obtain a product, and the contents of puerarin-7-O-glucoside crystals and puerarin-7-O-isomaltoside crystals are b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses a puerarin glycosylation derivative, a medicine compound thereof, a preparation method and application thereof, in particular to the puerarin glycosylation derivative of Formula (I) or a medical acceptable salt thereof, wherein R is a monose base (hexose or pentose) or an oligose base (connecting 2 to 5 hexose or pentose ). The medical acceptable salt is compounded salt of inorganic base or organic base. The puerarin glycosylation derivative or the medical acceptable salt thereof of the invention has better stability and water-solubility, promotes the bioavailability and enhances the healing effect.

Description

technical field [0001] The present invention relates to the field of medicine, in particular to a new puerarin derivative and its pharmaceutical composition and preparation method, as well as preparation, treatment and prevention of cardiovascular and cerebrovascular diseases, atherosclerosis, lowering blood fat, diabetic nephropathy and insulin resistance, Use of anti-osteoporosis drugs. Background technique [0002] Puerarin is an active ingredient extracted from Radix Puerariae. It is a commonly used natural medicine and is recorded in the national drug standards. It is mainly used for coronary heart disease, angina pectoris, myocardial infarction, ischemic cerebrovascular disease, Retinal arteriovenous thrombosis, sudden deafness, etc. Puerarin preparations include injections, freeze-dried powder injections, and eye drops. The actual use is mainly clinical application by injection. With the extension of clinical use time, some adverse reactions appear, mainly because: ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07H17/07C12P19/60A61K31/7048A61P9/10A61P3/06A61P3/10A61P19/10C12R1/01
Inventor 袁生丛晓东丁选胜徐海东于赐刚张云
Owner NANJING NORMAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com